Skip to main content
. Author manuscript; available in PMC: 2025 Sep 1.
Published in final edited form as: Gynecol Oncol. 2024 Jun 27;188:52–57. doi: 10.1016/j.ygyno.2024.06.008

Figure 2: Folate receptor alpha (FRα)-high expression is enriched amongst low-grade serous carcinomas lacking MAPK pathway genetic alterations.

Figure 2:

Oncoprint showing indicated MAPK pathway genetic alterations, with folate receptor alpha (FRα) status and expression level (percentage of FRα-positive tumor cells) per sample.